GBNH Greenbrook TMS Inc.

Operating through 126 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:GTMS.

$12.83
As of 06/24/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Care Facilities
Index country:  Canada
Country of incorporation:  
IPO date:  03/15/2021
Outstanding shares:  16,089,135
Average volume:  8,976
Market cap:   $204,332,015
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -6.21
PB ratio:   -200.68
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy